[en] Precision medicine in neuro-oncology hinges on our ability to decode the molecular and functional complexity of brain tumours. These tumours are highly heterogeneous and dynamic ecosystems that remain challenging to replicate with traditional experimental models. Organoids have emerged as next-generation tools for capturing the diversity of brain tumours in a clinically relevant context. Here, we review advances in applying organoids as tumour avatars to foster precision medicine. We assess current methodologies for generating organoids from various brain tumour types and illustrate how these models have enhanced mechanistic insight into tumour initiation, progression and resistance to treatment. Furthermore, we explore their translational potential in functional drug screening and treatment stratification, offering a powerful preclinical and co-clinical platform with which to personalize neuro-oncology.
Disciplines :
Oncology
Author, co-author :
de Lucas Sanz, Marta; NORLUX Neuro-Oncology Laboratory, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg ; Department of Life Sciences and Medicine, Faculty of Science, Technology and Medicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg
NICLOU, Simone ; University of Luxembourg > Faculty of Science, Technology and Medicine (FSTM) > Department of Health, Medicine and Life Sciences (DHML)
GOLEBIEWSKA, Anna ; University of Luxembourg ; NORLUX Neuro-Oncology Laboratory, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg. anna.golebiewska@lih.lu
External co-authors :
no
Language :
English
Title :
Modelling brain tumours with organoids: towards precision medicine in neuro-oncology.
FNR - Fonds National de la Recherche Luxembourg European Union's Horizon Europe Marie Skłodowska-Curie Doctoral Network
Funding number :
C21/BM/15739125/DIOMEDES; 20/BM/14646004/GLASSLUX; MITOFIT INTER/GACR/23/18089030; No 101073386 (GLIORESOLVE)
Funding text :
We acknowledge the support from the Luxembourg Institute of Health, the University of Luxembourg, the Luxembourg National Research Fund and Fondation Cancer Luxembourg (C21/BM/15739125/DIOMEDES, C20/BM/14646004/GLASSLUX, MITOFIT INTER/GACR/23/18089030) and EU COST Action NET4BRAIN CA22103. This project has received funding from the European Union's Horizon Europe research and innovation programme under the Marie Skłodowska-Curie Doctoral Networks grant agreement No 101073386 (GLIORESOLVE).
Louis DN et al. The 2021 WHO classification of tumors of the central nervous system: a summary Neuro Oncol. 2021 23 1231 1251 1:CAS:528:DC%2BB3MXisFSht73J 34185076 8328013 10.1093/neuonc/noab106
Aldape K et al. cIMPACT-NOW update 9: recommendations on utilization of genome-wide DNA methylation profiling for central nervous system tumor diagnostics Neurooncol. Adv. 2025 7 39902391 11788596 vdae228
Bouffet E et al. Dabrafenib plus trametinib in pediatric glioma with BRAF V600 mutations N. Engl. J. Med. 2023 389 1108 1120 1:CAS:528:DC%2BB3sXhvFOitrvK 37733309 10.1056/NEJMoa2303815
Mellinghoff IK et al. Vorasidenib in IDH1- or IDH2-mutant low-grade glioma N. Engl. J. Med. 2023 389 589 601 1:CAS:528:DC%2BB3sXhslWlt7zP 37272516 11445763 10.1056/NEJMoa2304194
van den Bent MJ et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034 J. Clin. Oncol. 2009 27 1268 1274 19204207 2667826 10.1200/JCO.2008.17.5984
Reardon DA et al. A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma Clin. Cancer Res. 2013 19 900 908 1:CAS:528:DC%2BC3sXislOqtL0%3D 23363814 10.1158/1078-0432.CCR-12-1707
Moreno-Sanchez PM Rezaeipour M Inderberg EM Platten M Golebiewska A Immunosuppressive mechanisms and therapeutic interventions shaping glioblastoma immunity Nat. Cancer 2026 7 29 42 1:CAS:528:DC%2BB28Xht1Gmsb0%3D 41507535 10.1038/s43018-025-01097-9
Aldape K et al. Challenges to curing primary brain tumours Nat. Rev. Clin. Oncol. 2019 16 509 520 1:CAS:528:DC%2BC1MXhtVyjtrvN 30733593 6650350 10.1038/s41571-019-0177-5
Yabo YA Niclou SP Golebiewska A Cancer cell heterogeneity and plasticity: a paradigm shift in glioblastoma Neuro Oncol. 2022 24 669 682 1:CAS:528:DC%2BB38XjtVahsrvF 34932099 9071273 10.1093/neuonc/noab269
Ostrom QT Cioffi G Waite K Kruchko C Barnholtz-Sloan JS CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014–2018 Neuro Oncol. 2021 23 iii1 iii105 34608945 8491279 10.1093/neuonc/noab200
Clark MJ et al. U87MG decoded: the genomic sequence of a cytogenetically aberrant human cancer cell line PLoS Genet. 2010 6 20126413 2813426 10.1371/journal.pgen.1000832 e1000832
Torsvik A et al. U-251 revisited: genetic drift and phenotypic consequences of long-term cultures of glioblastoma cells Cancer Med. 2014 3 812 824 1:CAS:528:DC%2BC2cXht12gurvJ 24810477 4303149 10.1002/cam4.219
Grasso CS et al. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma Nat. Med. 2015 21 555 559 1:CAS:528:DC%2BC2MXhtFemsbfO 25939062 4862411 10.1038/nm.3855
Damanskienė E et al. The different temozolomide effects on tumorigenesis mechanisms of pediatric glioblastoma PBT24 and SF8628 cell tumor in CAM model and on cells in vitro Int. J. Mol. Sci. 2022 23 2001 35216113 8877228 10.3390/ijms23042001
Hashizume R et al. Characterization of a diffuse intrinsic pontine glioma cell line: implications for future investigations and treatment J. Neurooncol. 2012 110 305 313 22983601 10.1007/s11060-012-0973-6
Ramsawhook A Lewis L Coyle B Ruzov A Medulloblastoma and ependymoma cells display increased levels of 5-carboxylcytosine and elevated TET1 expression Clin. Epigenet. 2017 9 10.1186/s13148-016-0306-2 18
Dobson T Swaminathan J Chromatin immunoprecipitation assays on medulloblastoma cell line DAOY Methods Mol. Biol. 2022 2423 39 50 1:CAS:528:DC%2BB3sXis1Ghu7g%3D 34978686 10.1007/978-1-0716-1952-0_4
Rosenberg S et al. Multi-omics analysis of primary glioblastoma cell lines shows recapitulation of pivotal molecular features of parental tumors Neuro Oncol. 2017 19 219 228 1:CAS:528:DC%2BC1cXitFSntrrK 27571888 5463853
Ntafoulis I et al. Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers Br. J. Cancer 2023 129 1327 1338 1:CAS:528:DC%2BB3sXhslOht7jE 37620410 10575865 10.1038/s41416-023-02402-y
Kim S-C et al. Patient-derived glioblastoma cell lines with conserved genome profiles of the original tissue Sci. Data 2023 10 1:CAS:528:DC%2BB3sXhsVOmt7jK 37438387 10338444 10.1038/s41597-023-02365-y 448
Pedace L et al. Evaluating cell culture reliability in pediatric brain tumor primary cells through DNA methylation profiling npj Precis. Oncol. 2024 8 92 1:CAS:528:DC%2BB2cXhtVaqtLvM 38637626 11026496 10.1038/s41698-024-00578-x
Schulte A et al. Glioblastoma stem-like cell lines with either maintenance or loss of high-level EGFR amplification, generated via modulation of ligand concentration Clin. Cancer Res. 2012 18 1901 1913 1:CAS:528:DC%2BC38XkvFOmu70%3D 22316604 10.1158/1078-0432.CCR-11-3084
Letchuman V et al. Syngeneic murine glioblastoma models: reactionary immune changes and immunotherapy intervention outcomes Neurosurg. Focus. 2022 52 E5 35104794 10851929 10.3171/2021.11.FOCUS21556
Grigore F-N Yang SJ Chen CC Koga T Pioneering models of pediatric brain tumors Neoplasia 2023 36 1:CAS:528:DC%2BB38XjtV2ls77N 36599191 9823239 10.1016/j.neo.2022.100859 100859
Brandner S Rodent models of tumours of the central nervous system Mol. Oncol. 2024 18 2842 2870 1:CAS:528:DC%2BB2cXitVKgurrF 39324445 11619804 10.1002/1878-0261.13729
Steindl A Valiente M Potential of ex vivo organotypic slice cultures in neuro-oncology Neuro Oncol. 2025 27 338 351 39504579 11812025 10.1093/neuonc/noae195
Lee S et al. High-throughput identification of repurposable neuroactive drugs with potent anti-glioblastoma activity Nat. Med. 2024 30 3196 3208 1:CAS:528:DC%2BB2cXitVegt77J 39304781 11564103 10.1038/s41591-024-03224-y
Golebiewska A et al. Patient-derived organoids and orthotopic xenografts of primary and recurrent gliomas represent relevant patient avatars for precision oncology Acta Neuropathol. 2020 140 919 949 1:CAS:528:DC%2BB3cXhvFyitrzE 33009951 7666297 10.1007/s00401-020-02226-7
Lago C et al. Patient- and xenograft-derived organoids recapitulate pediatric brain tumor features and patient treatments EMBO Mol. Med. 2023 15 1:CAS:528:DC%2BB3sXisFait7fN 38037472 10701620 10.15252/emmm.202318199 e18199
Cudalbu C et al. Metabolic and transcriptomic profiles of glioblastoma invasion revealed by comparisons between patients and corresponding orthotopic xenografts in mice Acta Neuropathol. Commun. 2021 9 133 1:CAS:528:DC%2BB3MXhvFSrsLrI 34348785 8336020 10.1186/s40478-021-01232-4
Yabo YA et al. Glioblastoma-instructed microglia transition to heterogeneous phenotypic states with phagocytic and dendritic cell-like features in patient tumors and patient-derived orthotopic xenografts Genome Med. 2024 16 1:CAS:528:DC%2BB2cXnsVKlsrc%3D 38566128 10988817 10.1186/s13073-024-01321-8 51
Bjerkvig R Tønnesen A Laerum OD Backlund EO Multicellular tumor spheroids from human gliomas maintained in organ culture J. Neurosurg. 1990 72 463 475 1:STN:280:DyaK3c7lsFCltQ%3D%3D 2406382 10.3171/jns.1990.72.3.0463
Jacob F et al. A patient-derived glioblastoma organoid model and Biobank recapitulates inter- and intra-tumoral heterogeneity Cell 2020 180 188 204.e22 1:CAS:528:DC%2BB3cXhvFCqtw%3D%3D 31883794 10.1016/j.cell.2019.11.036
Bougnaud S et al. Molecular crosstalk between tumour and brain parenchyma instructs histopathological features in glioblastoma Oncotarget 2016 7 31955 31971 27049916 5077988 10.18632/oncotarget.7454
Jacob F Ming G Song H Generation and biobanking of patient-derived glioblastoma organoids and their application in CAR T cell testing Nat. Protoc. 2020 15 4000 4033 1:CAS:528:DC%2BB3cXit1yhtLzJ 33169003 10.1038/s41596-020-0402-9
Shekarian T et al. Immunotherapy of glioblastoma explants induces interferon-γ responses and spatial immune cell rearrangements in tumor center, but not periphery Sci. Adv. 2022 8 1:CAS:528:DC%2BB38XitVersb3E 35776791 10883360 10.1126/sciadv.abn9440 eabn9440
Hubert CG et al. A three-dimensional organoid culture system derived from human glioblastomas recapitulates the hypoxic gradients and cancer stem cell heterogeneity of tumors found in vivo Cancer Res. 2016 76 2465 2477 1:CAS:528:DC%2BC28XmtVagsLk%3D 26896279 4873351 10.1158/0008-5472.CAN-15-2402
Chadwick M et al. Rapid processing and drug evaluation in glioblastoma patient-derived organoid models with 4d bioprinted arrays iScience 2020 23 1:CAS:528:DC%2BB3cXhsFSitb7M 32731171 7393526 10.1016/j.isci.2020.101365 101365
Oudin A et al. Protocol for derivation of organoids and patient-derived orthotopic xenografts from glioma patient tumors STAR Protoc. 2021 2 1:CAS:528:DC%2BB38Xhs1yis77E 34027491 8132120 10.1016/j.xpro.2021.100534 100534
Wöllner A et al. Use of tissue specimens from stereotactic biopsies for patient-derived GBM organoid-based drug testing Cells 2025 14 701 40422204 12109714 10.3390/cells14100701
Deligne C et al. Establishing a living biobank of pediatric high-grade glioma and ependymoma suitable for cancer pharmacology Neuro Oncol. 2025 27 1325 1340 39792378 12187455 10.1093/neuonc/noaf007
Yamazaki S et al. Newly established patient-derived organoid model of intracranial meningioma Neuro Oncol. 2021 23 1936 1948 1:CAS:528:DC%2BB3MXislSqu7zF 34214169 8563327 10.1093/neuonc/noab155
Zhao Z et al. Organoids Nat. Rev. Methods Primers 2022 2 94 1:CAS:528:DC%2BB38XjtVaju77K 37325195 10270325 10.1038/s43586-022-00174-y
Rossi G Manfrin A Lutolf MP Progress and potential in organoid research Nat. Rev. Genet. 2018 19 671 687 1:CAS:528:DC%2BC1cXhslCjurfF 30228295 10.1038/s41576-018-0051-9
Kim J et al. Assembly of glioblastoma tumoroids and cerebral organoids: a 3D in vitro model for tumor cell invasion Mol. Oncol. 2025 19 698 715 1:CAS:528:DC%2BB2cXisVSltrbO 39473365 10.1002/1878-0261.13740
Verduin M et al. Patient-derived glioblastoma organoids reflect tumor heterogeneity and treatment sensitivity Neurooncol. Adv. 2023 5 38130902 10733660 vdad152
Schuster A et al. AN1-type zinc finger protein 3 (ZFAND3) is a transcriptional regulator that drives glioblastoma invasion Nat. Commun. 2020 11 1:CAS:528:DC%2BB3cXis1Wltb3O 33311477 7732990 10.1038/s41467-020-20029-y 6366
Tetzlaff SK et al. Characterizing and targeting glioblastoma neuron-tumor networks with retrograde tracing Cell 2025 188 390 411.e36 1:CAS:528:DC%2BB2cXis12nurzE 39644898 10.1016/j.cell.2024.11.002
Chen C-C et al. Patient-derived tumor organoids as a platform of precision treatment for malignant brain tumors Sci. Rep. 2022 12 1:CAS:528:DC%2BB38XisFOhur3N 36180511 9525286 10.1038/s41598-022-20487-y 16399
Abdullah KG et al. Establishment of patient-derived organoid models of lower-grade glioma Neuro Oncol. 2021 24 612 623 10.1093/neuonc/noab273
Soares-Ferreira B et al. Patient-derived tumoroids recapitulate the morphologic and molecular features of pediatric brain tumors npj Precis. Oncol. 2025 9 371 1:CAS:528:DC%2BB2MXjtF2rtLbE 41315743 12663098 10.1038/s41698-025-01151-w
LeBlanc VG et al. Single-cell landscapes of primary glioblastomas and matched explants and cell lines show variable retention of inter- and intratumor heterogeneity Cancer Cell 2022 40 379 392.e9 1:CAS:528:DC%2BB38Xntlyns7Y%3D 35303420 10.1016/j.ccell.2022.02.016
Lancaster MA et al. Cerebral organoids model human brain development and microcephaly Nature 2013 501 373 379 1:CAS:528:DC%2BC3sXhtlCntb3F 23995685 3817409 10.1038/nature12517
Lancaster MA Knoblich JA Generation of cerebral organoids from human pluripotent stem cells Nat. Protoc. 2014 9 2329 2340 1:CAS:528:DC%2BC2cXhsVyhu7%2FO 25188634 4160653 10.1038/nprot.2014.158
Muguruma K Nishiyama A Kawakami H Hashimoto K Sasai Y Self-organization of polarized cerebellar tissue in 3D culture of human pluripotent stem cells Cell Rep. 2015 10 537 550 1:CAS:528:DC%2BC2MXhvVOqtbw%3D 25640179 10.1016/j.celrep.2014.12.051
Velasco S et al. Individual brain organoids reproducibly form cell diversity of the human cerebral cortex Nature 2019 570 523 527 1:CAS:528:DC%2BC1MXhtFWqtLfM 31168097 6906116 10.1038/s41586-019-1289-x
Joseph JV et al. TGF-β promotes microtube formation in glioblastoma through thrombospondin 1 Neuro Oncol. 2022 24 541 553 1:CAS:528:DC%2BB38XjtVahsrrK 34543427 8972291 10.1093/neuonc/noab212
Zhou W et al. Development of a highly differentiated rat brain organoid model for exploring glioblastoma invasion dynamics and therapy Neuro Oncol. 2025 24 10.1093/neuonc/noaf271 noaf271
Huang M et al. Engineering genetic predisposition in human neuroepithelial stem cells recapitulates medulloblastoma tumorigenesis Cell Stem Cell 2019 25 433 446.e7 1:CAS:528:DC%2BC1MXhtFOku7bP 31204176 6731167 10.1016/j.stem.2019.05.013
Koga T et al. Longitudinal assessment of tumor development using cancer avatars derived from genetically engineered pluripotent stem cells Nat. Commun. 2020 11 1:CAS:528:DC%2BB3cXksFals7s%3D 31992716 6987220 10.1038/s41467-020-14312-1 550
Haag D et al. H3.3-K27M drives neural stem cell-specific gliomagenesis in a human iPSC-derived model Cancer Cell 2021 39 407 422.e13 1:CAS:528:DC%2BB3MXjs1yrt7o%3D 33545065 10.1016/j.ccell.2021.01.005
Bian S et al. Genetically engineered cerebral organoids model brain tumour formation Nat. Methods 2018 15 631 639 1:CAS:528:DC%2BC1cXhtlOis7vP 30038414 6071863 10.1038/s41592-018-0070-7
Wang C et al. A multidimensional atlas of human glioblastoma-like organoids reveals highly coordinated molecular networks and effective drugs npj Precis. Oncol. 2024 8 19 38273014 10811239 10.1038/s41698-024-00500-5
Singh SK et al. TP53-PTEN-NF1 depletion in human brain organoids produces a glioma phenotype in vitro Front. Oncol. 2023 13 1:CAS:528:DC%2BB2cXpvFKjug%3D%3D 37881491 10597663 10.3389/fonc.2023.1279806 1279806
Parisian AD et al. SMARCB1 loss interacts with neuronal differentiation state to block maturation and impact cell stability Genes. Dev. 2020 34 1316 1329 1:CAS:528:DC%2BB3cXitlyltbfO 32912900 7528703 10.1101/gad.339978.120
Ballabio C et al. Modeling medulloblastoma in vivo and with human cerebellar organoids Nat. Commun. 2020 11 1:CAS:528:DC%2BB3cXksFahtrg%3D 31996670 6989674 10.1038/s41467-019-13989-3 583
Kim H-M Lee S-H Lim J Yoo J Hwang D-Y The epidermal growth factor receptor variant type III mutation frequently found in gliomas induces astrogenesis in human cerebral organoids Cell Prolif. 2021 54 1:CAS:528:DC%2BB3MXptVKitro%3D 33283409 10.1111/cpr.12965 e12965
Ishahak M et al. Genetically engineered brain organoids recapitulate spatial and developmental states of glioblastoma progression Adv. Sci. 2025 12 1:CAS:528:DC%2BB2MXislaiur4%3D 10.1002/advs.202410110 2410110
Ogawa J Pao GM Shokhirev MN Verma IM Glioblastoma model using human cerebral organoids Cell Rep. 2018 23 1220 1229 1:CAS:528:DC%2BC1cXotlGnurw%3D 29694897 6892608 10.1016/j.celrep.2018.03.105
Hwang JW et al. A novel neuronal organoid model mimicking glioblastoma (GBM) features from induced pluripotent stem cells (iPSC) Biochim. Biophys. Acta 2020 1864 1:CAS:528:DC%2BB3cXitFent7g%3D 10.1016/j.bbagen.2020.129540 129540
Eichmüller OL et al. Amplification of human interneuron progenitors promotes brain tumors and neurological defects Science 2022 375 35084981 7613689 10.1126/science.abf5546 eabf5546
Lago C et al. Medulloblastoma and high-grade glioma organoids for drug screening, lineage tracing, co-culture and in vivo assay Nat. Protoc. 2023 18 2143 2180 1:CAS:528:DC%2BB3sXhtFWgt7zJ 37248391 10.1038/s41596-023-00839-2
Prior VG et al. Parsing the effect of co-culture with brain organoids on Diffuse Intrinsic Pontine Glioma (DIPG) using quantitative proteomics Int. J. Biochem. Cell Biol. 2024 174 1:CAS:528:DC%2BB2cXhs1SjsrrF 39009182 10.1016/j.biocel.2024.106617 106617
van Essen MJ Nicheperovich A Schuster-Böckler B Becker EBE Jacob J Sonic hedgehog medulloblastoma cells in co-culture with cerebellar organoids converge towards in vivo malignant cell states Neurooncol. Adv. 2024 7 39896075 11783571 vdae218
Schickel E et al. Human cerebral organoids model tumor initiation and infiltration in an autologous astrocyte-supported setting iScience 2025 28 1:CAS:528:DC%2BB2MXjtFagt7fP 40917877 12410359 10.1016/j.isci.2025.113334 113334
Peng T et al. Individualized patient tumor organoids faithfully preserve human brain tumor ecosystems and predict patient response to therapy Cell Stem Cell 2025 32 652 669.e11 1:CAS:528:DC%2BB2MXjsVajsb0%3D 39938519 10.1016/j.stem.2025.01.002
Kistemaker L van Bodegraven EJ de Vries HE Hol EM Vascularized human brain organoids: current possibilities and prospects Trends Biotechnol. 2025 43 1275 1285 1:CAS:528:DC%2BB2MXjtFGgsQ%3D%3D 39753489 10.1016/j.tibtech.2024.11.021
Park DS et al. iPS-cell-derived microglia promote brain organoid maturation via cholesterol transfer Nature 2023 623 397 405 1:CAS:528:DC%2BB3sXit1Klu73O 37914940 10.1038/s41586-023-06713-1
Sabate-Soler S et al. Microglia integration into human midbrain organoids leads to increased neuronal maturation and functionality Glia 2022 70 1267 1288 1:CAS:528:DC%2BB38XhtVals73F 35262217 9314680 10.1002/glia.24167
Ballabio C et al. Notch1 switches progenitor competence in inducing medulloblastoma Sci. Adv. 2021 7 1:CAS:528:DC%2BB3MXhvVSht7jO 34162555 8221631 10.1126/sciadv.abd2781 eabd2781
Clements M et al. Axonal injury is a targetable driver of glioblastoma progression Nature 2025 646 452 461 1:CAS:528:DC%2BB2MXitVCkurzI 40836081 12507684 10.1038/s41586-025-09411-2
Hamed AA et al. Gliomagenesis mimics an injury response orchestrated by neural crest-like cells Nature 2025 638 499 509 1:CAS:528:DC%2BB2MXisFyqug%3D%3D 39743595 11821533 10.1038/s41586-024-08356-2
Sundar SJ et al. Three-dimensional organoid culture unveils resistance to clinical therapies in adult and pediatric glioblastoma Transl. Oncol. 2022 15 1:CAS:528:DC%2BB38XhsVGht7bK 34700192 10.1016/j.tranon.2021.101251 101251
Sanzey M et al. Comprehensive analysis of glycolytic enzymes as therapeutic targets in the treatment of glioblastoma PLoS ONE 2015 10 25932951 4416792 10.1371/journal.pone.0123544 e0123544
Abdul Rahim SA et al. Regulation of hypoxia-induced autophagy in glioblastoma involves ATG9A Br. J. Cancer 2017 117 813 825 1:CAS:528:DC%2BC2sXhtlWhtbzJ 28797031 5590001 10.1038/bjc.2017.263
Golebiewska A et al. Side population in human glioblastoma is non-tumorigenic and characterizes brain endothelial cells Brain 2013 136 1462 1475 23460667 3634193 10.1093/brain/awt025
Oudin A Moreno-Sanchez PM Baus V Niclou SP Golebiewska A Magnetic resonance imaging-guided intracranial resection of glioblastoma tumors in patient-derived orthotopic xenografts leads to clinically relevant tumor recurrence BMC Cancer 2024 24 1:CAS:528:DC%2BB2cXptFSrug%3D%3D 38166949 10763155 10.1186/s12885-023-11774-6 3
Brabetz S et al. A biobank of patient-derived pediatric brain tumor models Nat. Med. 2018 24 1752 1761 1:CAS:528:DC%2BC1cXhvF2lsbrL 30349086 10.1038/s41591-018-0207-3
Stieber D et al. Glioblastomas are composed of genetically divergent clones with distinct tumourigenic potential and variable stem cell-associated phenotypes Acta Neuropathol. 2014 127 203 219 1:CAS:528:DC%2BC3sXhs1yqsb%2FF 24154962 10.1007/s00401-013-1196-4
da Silva B Mathew RK Polson ES Williams J Wurdak H Spontaneous glioblastoma spheroid infiltration of early-stage cerebral organoids models brain tumor invasion SLAS Discov. 2018 23 862 868 29543559 10.1177/2472555218764623
Linkous A et al. Modeling patient-derived glioblastoma with cerebral organoids Cell Rep. 2019 26 3203 3211.e5 1:CAS:528:DC%2BC1MXls1KqtL8%3D 30893594 6625753 10.1016/j.celrep.2019.02.063
Krieger TG et al. Modeling glioblastoma invasion using human brain organoids and single-cell transcriptomics Neuro Oncol. 2020 22 1138 1149 32297954 7594554 10.1093/neuonc/noaa091
Suvà ML Tirosh I The glioma stem cell model in the era of single-cell genomics Cancer Cell 2020 37 630 636 32396858 10.1016/j.ccell.2020.04.001
Klein E Hau A-C Oudin A Golebiewska A Niclou SP Glioblastoma organoids: pre-clinical applications and challenges in the context of immunotherapy Front. Oncol. 2020 10 604121 33364198 7753120 10.3389/fonc.2020.604121
Mangena V et al. Glioblastoma cortical organoids recapitulate cell-state heterogeneity and intercellular transfer Cancer Discov. 2025 15 299 315 1:CAS:528:DC%2BB2MXnslyktro%3D 39373549 11803396 10.1158/2159-8290.CD-23-1336
Raleigh, D. et al. Spatial synaptic connectivity underlies oligodendroglioma evolution and recurrence. Preprint at Research Squarehttps://doi.org/10.21203/rs.3.rs-6299872/v1 (2025).
Ermini, L. et al. Integrative multi-omics combined with functional pharmacological profiling in patient-derived organoids identifies personalized therapeutic vulnerabilities of adult high-grade gliomas. Preprint at bioRxivhttps://doi.org/10.1101/2025.09.09.675145 (2025).
Majc B et al. Patient-derived tumor organoids mimic treatment-induced DNA damage response in glioblastoma iScience 2024 27 1:CAS:528:DC%2BB2cXhvVGlsbfP 39252971 11381849 10.1016/j.isci.2024.110604 110604
Moore Z et al. Patient-derived organoids and neurospheres recapitulate salient features of primary tumor heterogeneity Neurooncol. Adv. 2025 8 41531794 12795600 vdaf247
Roth JG et al. Spatially controlled construction of assembloids using bioprinting Nat. Commun. 2023 14 1:CAS:528:DC%2BB3sXhsFejsLfJ 37468483 10356773 10.1038/s41467-023-40006-5 4346
Logun M et al. Patient-derived glioblastoma organoids as real-time avatars for assessing responses to clinical CAR-T cell therapy Cell Stem Cell 2025 32 181 190.e4 1:CAS:528:DC%2BB2cXislWks73K 39657679 10.1016/j.stem.2024.11.010
Salvato I et al. Adenoviral delivery of the CIITA transgene induces T-cell-mediated killing in glioblastoma organoids Mol. Oncol. 2025 19 682 697 1:CAS:528:DC%2BB2cXisFyjsb7I 39535369 10.1002/1878-0261.13750
Chiavelli C Autologous anti-GD2 CAR T cells efficiently target primary human glioblastoma npj Precis. Oncol. 2024 10.1038/s41698-024-00506-z 38302615 10834575
Zheng C et al. A novel organoid model retaining the glioma microenvironment for personalized drug screening and therapeutic evaluation Bioact. Mater. 2025 53 205 217 1:CAS:528:DC%2BB2MXitlahsbbL 40697395 12281051
Soubéran A et al. Brain tumoroids: treatment prediction and drug development for brain tumors with fast, reproducible, and easy-to-use personalized models Neuro Oncol. 2025 27 415 429 39252580 11812045 10.1093/neuonc/noae184
Fermi V et al. Effective reprogramming of patient-derived m2-polarized glioblastoma-associated microglia/macrophages by treatment with GW2580 Clin. Cancer Res. 2023 29 4685 4697 1:CAS:528:DC%2BB2cXmt1Oktg%3D%3D 37682326 10.1158/1078-0432.CCR-23-0576
Jungwirth, G. et al. Personalized medicine for meningiomas: drug screening on tumor organoids exposes therapeutic vulnerabilities to HDAC1/2i panobinostat. Preprint at bioRxivhttps://doi.org/10.1101/2024.11.26.625347 (2024).
Wijnakker JJAPM et al. Integrin-activating Yersinia protein Invasin sustains long-term expansion of primary epithelial cells as 2D organoid sheets Proc. Natl Acad. Sci. USA 2025 122 1:CAS:528:DC%2BB2MXjtV2jsr0%3D 39793062 10.1073/pnas.2420595121 e2420595121
Berghoff AS et al. Personalized targeted glioblastoma therapies by ex vivo drug screening: study protocol of the advanced brain tumor therapy clinical trial (ATTRACT) Neurooncol. Adv. 2025 7 40351832 12063086 vdaf056
Ratliff M et al. Patient-derived tumor organoids for guidance of personalized drug therapies in recurrent glioblastoma Int. J. Mol. Sci. 2022 23 6572 1:CAS:528:DC%2BB38Xhs1OjsrnM 35743016 9223608 10.3390/ijms23126572
Letai A Functional precision cancer medicine—moving beyond pure genomics Nat. Med. 2017 23 1028 1035 1:CAS:528:DC%2BC2sXhsVKgtbrN 28886003 10.1038/nm.4389
Cantini L et al. Benchmarking joint multi-omics dimensionality reduction approaches for the study of cancer Nat. Commun. 2021 12 1:CAS:528:DC%2BB3MXnsV2gtg%3D%3D 33402734 7785750 10.1038/s41467-020-20430-7 124
Wu M et al. Multi-omics and pharmacological characterization of patient-derived glioma cell lines Nat. Commun. 2024 15 1:CAS:528:DC%2BB2cXhslKnsLjI 39112531 11306361 10.1038/s41467-024-51214-y 6740
Stavrakaki E et al. Ultrasonic aspiration-acquired glioblastoma tissue preserves lymphocyte phenotype and viability, supporting its use for immunological studies Cancers 2025 17 603 1:CAS:528:DC%2BB2MXltFKgtLg%3D 40002198 11853073 10.3390/cancers17040603
Posthoorn-Verheul C et al. Optimized culturing yields high success rates and preserves molecular heterogeneity, enabling personalized screening for high-grade gliomas npj Precis. Oncol. 2025 9 156 40425813 12116786 10.1038/s41698-025-00946-1
Volovetz J et al. The importance of integrating surgical resection into preclinical glioblastoma modeling Clin. Cancer Res. 2025 31 4032 4039 1:CAS:528:DC%2BB28XlsFGru74%3D 40788294 10.1158/1078-0432.CCR-25-0788
Neises L et al. Protocol using ex vivo mouse brain slice culture mimicking in vivo conditions to study tumor growth and cell motility of glioblastoma cells STAR Protoc. 2024 5 1:CAS:528:DC%2BB2cXitlyqsr7I 39425931 11532992 10.1016/j.xpro.2024.103401 103401
Connor K Golebiewska A Byrne AT Challenging the status quo to improve the translational potential of preclinical oncology studies Nat. Rev. Cancer 2025 25 3 4 1:CAS:528:DC%2BB2cXitFyhs7vF 39375534 10.1038/s41568-024-00756-w
Bose S et al. A path to translation: how 3D patient tumor avatars enable next generation precision oncology Cancer Cell 2022 40 1448 1453 36270276 10576652 10.1016/j.ccell.2022.09.017
Pașca SP et al. A nomenclature consensus for nervous system organoids and assembloids Nature 2022 609 907 910 36171373 10571504 10.1038/s41586-022-05219-6
Sun Y et al. Cholinergic neuron-to-glioblastoma synapses in a human iPSC-derived co-culture model Stem Cell Rep. 2025 20 1:CAS:528:DC%2BB2MXhsVWqtLrN 10.1016/j.stemcr.2025.102534 102534
Sørensen MD et al. Microglia induce an interferon-stimulated gene expression profile in glioblastoma and increase glioblastoma resistance to temozolomide Neuropathol. Appl. Neurobiol. 2024 50 39558550 11618491 10.1111/nan.13016 e13016
Jiang S et al. An automated organoid platform with inter-organoid homogeneity and inter-patient heterogeneity Cell Rep. Med. 2020 1 1:CAS:528:DC%2BB38XhvFWhs7rL 33377132 7762778 10.1016/j.xcrm.2020.100161 100161
Bayona C et al. A novel multicompartment barrier-free microfluidic device reveals the impact of extracellular matrix stiffening and temozolomide on immune-tumor interactions in glioblastoma Small 2025 21 39901479 10.1002/smll.202409229 e2409229
Gamboa CM et al. Generation of glioblastoma patient-derived organoids and mouse brain orthotopic xenografts for drug screening STAR Protoc. 2021 2 1:CAS:528:DC%2BB38XitVKhtr3L 33665625 7903462 10.1016/j.xpro.2021.100345 100345
Chan HSC et al. Establishment and characterization of meningioma patient-derived organoid J. Clin. Neurosci. 2021 94 192 199 34863437 10.1016/j.jocn.2021.10.035
Kim D et al. Establishment of tumor microenvironment-preserving organoid model from patients with intracranial meningioma Cancer Cell Int. 2024 24 1:CAS:528:DC%2BB2cXitFOhsrw%3D 38238738 10795458 10.1186/s12935-024-03225-4 36
Antonica F et al. A slow-cycling/quiescent cells subpopulation is involved in glioma invasiveness Nat. Commun. 2022 13 1:CAS:528:DC%2BB38XitFOltLzI 35970913 9378633 10.1038/s41467-022-32448-0 4767
Bagley JA Reumann D Bian S Lévi-Strauss J Knoblich JA Fused cerebral organoids model interactions between brain regions Nat. Methods 2017 14 743 751 1:CAS:528:DC%2BC2sXnslKkt7s%3D 28504681 5540177 10.1038/nmeth.4304
Lancaster MA et al. Guided self-organization and cortical plate formation in human brain organoids Nat. Biotechnol. 2017 35 659 666 1:CAS:528:DC%2BC2sXpt1Omsr8%3D 28562594 5824977 10.1038/nbt.3906
Miura Y et al. Engineering brain assembloids to interrogate human neural circuits Nat. Protoc. 2022 17 15 35 1:CAS:528:DC%2BB38XmsVersg%3D%3D 34992269 10.1038/s41596-021-00632-z
Birey F et al. Assembly of functionally integrated human forebrain spheroids Nature 2017 545 54 59 1:CAS:528:DC%2BC2sXmslehs70%3D 28445465 5805137 10.1038/nature22330
van Essen, M. J., Nayler, S., Apsley, E. J., Jacob, J. & Becker, E. B. E. in Measuring Cerebellar Function (ed. Sillitoe, R. V.) 1–21 (Humana Press, 2022).
Sloan SA Andersen J Pașca AM Birey F Pașca SP Generation and assembly of human brain region–specific three-dimensional cultures Nat. Protoc. 2018 13 2062 2085 1:CAS:528:DC%2BC1cXhs12ntr%2FO 30202107 6597009 10.1038/s41596-018-0032-7
Jiang X et al. Organoids: opportunities and challenges of cancer therapy Front. Cell Dev. Biol. 2023 11 1232528 37576596 10413981 10.3389/fcell.2023.1232528
Xin-Yi J Yan-Ran W Pin-Ru D Shi-Yi Q Hai-Tao J Organoids in cancer therapies: a comprehensive review Front. Bioeng. Biotechnol. 2025 13 40766972 12322668 10.3389/fbioe.2025.1607488 1607488
Smith RC Tabar V Constructing and deconstructing cancers using human pluripotent stem cells and organoids Cell Stem Cell 2019 24 12 24 1:CAS:528:DC%2BC1cXisF2ht7fE 30581078 10.1016/j.stem.2018.11.012
Liu X et al. Recent progress on the organoids: techniques, advantages and applications Biomed. Pharmacother. 2025 185 1:CAS:528:DC%2BB2MXlt1Ghtr4%3D 40043462 10.1016/j.biopha.2025.117942 117942
Onesto MM Kim J Pasca SP Assembloid models of cell–cell interaction to study tissue and disease biology Cell Stem Cell 2024 31 1563 1573 1:CAS:528:DC%2BB2cXitleisLzP 39454582 12143640 10.1016/j.stem.2024.09.017
Sadée C et al. Medical digital twins: enabling precision medicine and medical artificial intelligence Lancet Digital Health 2025 7 100864 40518342 12412312 10.1016/j.landig.2025.02.004
Meng F Xi Y Huang J Ayers PW A curated diverse molecular database of blood–brain barrier permeability with chemical descriptors Sci. Data 2021 8 1:CAS:528:DC%2BB38XksFartLk%3D 34716354 8556334 10.1038/s41597-021-01069-5 289
Nabi AE Pouladvand P Liu L Hua N Ayubcha C Machine learning in drug development for neurological diseases: a review of blood brain barrier permeability prediction models Mol. Inf. 2025 44 1:CAS:528:DC%2BB2MXnslentbg%3D 10.1002/minf.202400325 e202400325
